durvalumab,sorafenib,tremelimumab
astrazeneca,pfizer
['himalaya', 'lung', 'durva']
9+ mth imp. os for pt with vs w/out irae in himalaya trial in durva &gt;treme arm, but not single agent durva. no irae still benefited. why not pdl1? irae ~assoc w/ better os for pd1 in lung/mel, pdl1 effect less reliant on systemic response? #asco23 
attempting to strike a balance between motherhood, medical oncology, immunology research and *life (*stuff that happens in between)